Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033-1310, USA.
Covance Market Access Services Inc., 3rd Floor, 97 Waterloo Rd, Macquarie Park, NSW 2113, Australia.
J Glob Antimicrob Resist. 2018 Sep;14:33-44. doi: 10.1016/j.jgar.2018.02.005. Epub 2018 Feb 15.
Treating infections of Gram-negative pathogens, in particular Pseudomonas aeruginosa, is a challenge for clinicians in the Asia-Pacific region owing to inherent and acquired antimicrobial resistance. This systematic review and meta-analysis provides updated information on risk factors for P. aeruginosa infection in Asia-Pacific as well as the consequences (e.g. mortality, costs) of initial inappropriate antimicrobial therapy (IIAT).
Embase and MEDLINE databases were searched for Asia-Pacific studies reporting the consequences of IIAT versus initial appropriate antimicrobial therapy (IAAT) in Gram-negative bacterial infections as well as risk factors for serious P. aeruginosa infection. A meta-analysis of unadjusted mortality was performed using a random-effects model.
A total of 22 studies reporting mortality and 13 reporting risk factors were identified. The meta-analysis demonstrated that mortality was significantly lower in patients receiving IAAT versus IIAT, with a 67% reduction observed for 28- or 30-day all-cause mortality (odds ratio=0.33, 95% confidence interval 0.20-0.55; P<0.001). Risk factors for serious P. aeruginosa infection include previous exposure to antimicrobials, mechanical ventilation and previous hospitalisation.
High rates of antimicrobial resistance in Asia-Pacific as well as the increased mortality associated with IIAT and the presence of risk factors for serious infection highlight the importance of access to newer and appropriate antimicrobials.
亚太地区临床医生在治疗革兰氏阴性病原体感染,尤其是铜绿假单胞菌感染时面临挑战,这是由于固有和获得性的抗菌药物耐药性所致。本系统评价和荟萃分析提供了亚太地区铜绿假单胞菌感染的危险因素以及初始不适当抗菌治疗(IIAT)的后果(如死亡率、成本)的最新信息。
检索 Embase 和 MEDLINE 数据库,以获取报告 IIAT 与初始适当抗菌治疗(IAAT)在革兰氏阴性菌感染中的后果以及严重铜绿假单胞菌感染危险因素的亚太地区研究。使用随机效应模型对未调整的死亡率进行荟萃分析。
共确定了 22 项报告死亡率的研究和 13 项报告危险因素的研究。荟萃分析表明,接受 IAAT 的患者死亡率明显低于接受 IIAT 的患者,28 天或 30 天全因死亡率降低 67%(优势比=0.33,95%置信区间 0.20-0.55;P<0.001)。严重铜绿假单胞菌感染的危险因素包括先前接触抗菌药物、机械通气和先前住院治疗。
亚太地区抗菌药物耐药率高,以及 IIAT 相关的死亡率增加和严重感染的危险因素存在,突显了获得新型和适当抗菌药物的重要性。